Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Lorraine Portelance

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2806-2951; OpenAlex author ID A5031842995. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper

Papers 11

  1. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label… Co-author DOI 10.1016/j.radonc.2023.110064↗
  2. Dosimetry impact of distinct gating strategies in cine MR image-guided breath-hold pancreatic cancer radiotherapy. Co-author DOI 10.1002/acm2.14078↗
  3. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable… Co-author DOI 10.1016/j.ijrobp.2023.05.023↗
  4. Dosimetry impact of gating latency in cine magnetic resonance image guided breath-hold pancreatic cancer radiotherapy. Co-author DOI 10.1088/1361-6560/ac53e0↗
  5. Predictive Value of Delta-Radiomics Texture Features in 0.35 Tesla Magnetic Resonance Setup Images Acquired During Stereotactic Ablative Radiotherapy of Pancre… Co-author DOI 10.3389/fonc.2022.807725↗
  6. Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study. Co-author DOI 10.1002/mp.14200↗
  7. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Co-author DOI 10.1002/cam4.2100↗
  8. Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer. First author DOI 10.1016/j.prro.2018.08.010↗
  9. Dosimetric analysis of stereotactic body radiation therapy for pancreatic cancer using MR-guided Tri-60Co unit, MR-guided LINAC, and conventional LINAC-based p… Last author DOI 10.1016/j.prro.2018.02.010↗
  10. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2015.08.010↗
  11. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1186/1471-2407-12-199↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eric A. Mellon · 5 shared papers, 2018–2022 · strength 0.55
  2. Fei Yang · 3 shared papers, 2020–2023 · strength 0.46
  3. Benjamin Oren Spieler · 3 shared papers, 2019–2022 · strength 0.39
  4. Nesrin Dogan · 3 shared papers, 2018–2022 · strength 0.36
  5. Michael Frederick Bassetti · 3 shared papers, 2019–2024 · strength 0.35
  6. Parag Jitendra Parikh · 3 shared papers, 2019–2024 · strength 0.35
  7. Percy P. Lee · 3 shared papers, 2019–2024 · strength 0.35
  8. Pan Hu · 2 shared papers, 2022–2023 · strength 0.34
  9. Yidong Yang · 2 shared papers, 2022–2023 · strength 0.34
  10. Garrett Simpson · 2 shared papers, 2020–2022 · strength 0.28
  11. Michael David Chuong · 2 shared papers, 2023–2024 · strength 0.27
  12. John Ng · 2 shared papers, 2023–2024 · strength 0.27
  13. Luca Boldrini · 2 shared papers, 2023–2024 · strength 0.27
  14. Kathryn Elizabeth Mittauer · 2 shared papers, 2023–2024 · strength 0.27
  15. Alex T. Price · 2 shared papers, 2023–2024 · strength 0.27
  16. Lorenzo Placidi · 2 shared papers, 2023–2024 · strength 0.27
  17. Adam Christopher Mueller · 2 shared papers, 2023–2024 · strength 0.27
  18. Bassem I. Zaki · 2 shared papers, 2023–2024 · strength 0.27
  19. Hyun Jee Kim · 2 shared papers, 2023–2024 · strength 0.27
  20. Joseph Douglas Mancias · 2 shared papers, 2023–2024 · strength 0.27
  21. Lauren E. Henke · 2 shared papers, 2023–2024 · strength 0.27
  22. Daniel A. Low · 2 shared papers, 2023–2024 · strength 0.27
  23. Yuyan Dong · 1 shared paper, 2023 · strength 0.18
  24. William H. Jin · 1 shared paper, 2022 · strength 0.16
  25. Nancy El-Bared · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.